EP0304684A1 - Verfahren zur Herstellung von Benzoxazin Derivaten - Google Patents

Verfahren zur Herstellung von Benzoxazin Derivaten Download PDF

Info

Publication number
EP0304684A1
EP0304684A1 EP88112555A EP88112555A EP0304684A1 EP 0304684 A1 EP0304684 A1 EP 0304684A1 EP 88112555 A EP88112555 A EP 88112555A EP 88112555 A EP88112555 A EP 88112555A EP 0304684 A1 EP0304684 A1 EP 0304684A1
Authority
EP
European Patent Office
Prior art keywords
compound
benzoxazine
dihydro
general formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88112555A
Other languages
English (en)
French (fr)
Inventor
Toshihiro C/O Daiichi Seiyaku Prod.Tech. Fujiwara
Hideaki C/O Daiichi Seiyaku Prod.Tech. Tsurumi
Yukio C/O Daiichi Seiyaku Prod.Tech. Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Publication of EP0304684A1 publication Critical patent/EP0304684A1/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Definitions

  • the present invention relates, in one aspect, to a process for producing ( ⁇ )-3-alkyl-3,4-dihydro-2H-­[1,4]benzoxazine derivatives and, in another aspect, to a process for producing optically active 3-alkyl-3,4-­dihydro-2H-[1,4]benzoxazine derivatives, especially (S)-3-alkyl-benzoxazine derivatives.
  • JP-A-62-87577 the term "JP-A” as used herein refers to a "published unexamined Japanese patent application” and EP-A-206,283.
  • the present invention relates, in a first aspect, to a process for producing a ( ⁇ )-3-alkyl-3,4-­dihydro-2H-[1,4]benzoxazine derivative of general formula (II) wherein X, Y and Z, which may be the same or different, each represents a hydrogen atom or a halogen atom and R represents a lower alkyl group having 1 to 6 carbon atoms, which comprises hydrogenating a 3-alkyl-2H-[1,4]-­benzoxazine derivative of general formula (I) wherein X, Y, Z and R have the same meanings as defined above.
  • the invention further relates to a process for producing a ( ⁇ )-3-alkyl-3,4-dihydro-2H-[1,4]benzoxazine derivative of general formula (II) which comprises: dehydrogenating an (R)-(+)-3-alkyl-3,4-dihydro-2H-[1,4]-­benzoxazine derivative of general formula (III) wherein X, Y and Z, which may be the same or different, each represents a hydrogen atom or a halogen atom and R represents a lower alkyl group having 1 to 6 carbon atoms to give a 3-alkyl-2H-[1,4]benzoxazine derivative of general formula (I), wherein X, Y, Z and R have the same meanings as defined above; and hydrogenating the compound (I).
  • this invention relates, in a second aspect, to the optical resolution of a ( ⁇ )-3-alkyl-3,4-­dihydro-2H-[1,4]benzoxazine derivative of general formula (II).
  • the invention is directed to the salts of an (S)-3-alkyl-benzoxazine derivative and an (R)-(-)-­camphor-10-sulfonic acid which has the general formula (V)′ wherein X, Y and Z, which may be the same or different, each represents a hydrogen atom or a halogen atom and R represents a lower alkyl group having 1 to 6 carbon atoms; and it is also directed to a process for producing an optically active benzoxazine derivative which comprises subjecting a ( ⁇ )-3-alkyl-3,4-dihydro-2H-[1,4]-­benzoxazine compound of general formula (II) wherein X, Y and Z, which may be the same or different, each represents
  • the resulting optically active compound is also useful as an intermediate for the production of, for example, (S)-(-)-9-fluoro-3-methyl-10-­(4-methyl-1-piperadinyl)-7-oxo-2,3-dihydro-7H-pyrido-­[1,2,3-de][1,4]benzoxazine-6-carboxylic acid (see, for example, JP-A-62-87577 and EP-A-206,283).
  • the present invention provides useful processes in that the optically active form of compound (II) can be produced with efficiency and high purity by the simple procedure of recrystallization employing less expensive optical resolution reagent and in that the optical resolution reagent can be used many times.
  • the present invention also provides a useful process of converting undesirable (R)-isomer of compound (II) into the racemic mixture. Through the combination of the optical resolution method of compound (II) and the racemization procedure of undesirable (R)-isomer, the yield of useful (S)-isomer of compound (II) is increased.
  • Figure 1 is a recrystallization flow diagram.
  • compound (I) was obtained by the dehydrogenation of (R)-isomer of compound (II), and from this compound (I), racemic compound (II) was reproducible through the hydrogenation.
  • the dehydrogenation reaction for conversion of compound (III) to compound (I) is carried out by treating compound (III) with a halogenating agent and a base in the presence or absence of a solvent at a temperature from about -100°C to room temperature, preferably at -80 to 10°C, for a period of about 1 to 120 minutes.
  • the above-mentioned base may be organic or inorganic, and the preferred base is an aliphatic tertiary amine such as trimethylamine, triethylamine, tripropylamine, N,N-diisopropylethylamine and so on.
  • the base may be used in virtually any desired proportion not less than equimolar with respect to compound (III) and may be used as a solvent of the reaction.
  • the halogenating agent may be virtually any known halogenating agent, such as chlorine, bromine, sulfuryl chloride, N-chlorosuccinimide (NCS), N-­bromosuccinimide (NBS), N-bromoacetamide, hypochlorous acid, hypobromous acid, t-butyl hypochlorite and so on.
  • the amount of the halogenating agent is also any desired except that it must be at least equimolar to compound (III), and is preferably 1 to 10 mols per mol of compound (III).
  • Typical examples of the solvent that can be used in this reaction include various solvents which are inert to the reaction, such as esters (e.g., ethyl acetate, propyl acetate, etc.), amides (e.g., N,N-­dimethylformamide, N,N-dimethylacetamide, etc.), ethers (e.g., tetrahydrofuran, 1,4-dioxane, etc.) and so on.
  • the solvent is generally used in the range of 0 to 50 parts by weight with respect to compound (III).
  • the compound (I) which forms by the dehydro­genation of compound (III) can be isolated as pure crystals by the known procedures such as recrystalliza­tion, silica gel chromatography, etc., but the hydrogena­tion reaction may be conducted without isolating compound (I).
  • the hydrogenation of compound (I) to compound (II) can be carried out by the known procedure per se, for example, by reduction using a metal hydride such as sodium borohydride, lithium borohydride, etc., or by catalytic hydrogenation using a catalyst such as palladium-on-carbon, platinum, Raney nickel, etc.
  • a metal hydride such as sodium borohydride, lithium borohydride, etc.
  • a catalyst such as palladium-on-carbon, platinum, Raney nickel, etc.
  • compound (II) After completion of the hydrogenation, compound (II) can be isolated and purified by the known method such as extraction, redistribution, concentration, crystallization, chromatography and so on.
  • the optical purity (% e.e.) of compound (II) or compound (III) was determined by the following procedure.
  • the "% e.e.” is an abbreviation for % enantiomer excess, and is a measure of an optical purity of an optically active compound (see, for example, Asymmetric Synthesis , Vol. 1, p. 45, 60, Academic Press, New York (1983), edited by J.D. Morrison et al.).
  • the "% e.e.” is calculated as follows: wherein (R) represents a molar ratio of (R)-isomer in percent, and (S) represents that of the (S)-isomer, when (R) + (S) is taken as 100%.
  • the present inventors have conducted extensive investigations to develop a method for optical resolution of racemic compound (II). It is the characteristic feature of this method that the resolution reagent is less expensive and readily recovered.
  • both compounds (II) and (IV) have one asymmetric carbon in each melolecule.
  • Compound (II) is composed of two enantiomeric isomers, and compound (IV) is also composed of two enantiomeric isomers.
  • Four diastereoisomeric salts can be derived by combining the enantiomeric isomer of compound (II) and enantiomeric isomer of compound (IV). The present inventors found that two salts among these four salts were less soluble in organic solvents and readily precipitated from the solvents.
  • the optical purity of the precipitated salt is increased by repetition of recrystallization.
  • the free optically active compound can be obtained by treating the isolated salt with a base and successive extraction with an organic solvent.
  • the optical purity of the salt is maintained even after the treatment with a base.
  • the optical resolution reagent (IV) can be recovered in good yield and purity from the aqueous phase after treatment of salt (V) with a base.
  • salt (V) is initiated either by adding the racemic compound (II) and specific optical isomer of compound (IV) to a solvent or by mixing a solution of racemic compound (II) dissolved in a carboxylic acid solvent with an aqueous solution of the specific isomer of compound (IV).
  • the mixture is stirred at 70 to 100°C for a period ranging from 30 minutes to 1 hour for the completion of dissolution and, then, further stirred under ice-cooling at 5 to 10°C for 2 to 18 hours for crystallization of salt (V).
  • seed crystals may have to be added when hardly crystallized in an early stage but the crystallization becomes progressively easier as the recrystallization procedure is repeated.
  • carboxylic acid such as acetic acid, propionic acid and butyric acid are preferable.
  • the most preferable one is acetic acid, and especially acetic acid with a water content of from 10 to 50% (v/v) is beneficial for the purpose.
  • the amount of the solvent is preferably in the range of 5 to 20 parts (v/w), and more preferably in the range of 10 to 20 parts (v/w), based on compound (II).
  • the crystallized salt (V) is collected by filtration, washed with a small quantity of the same solvent as used in the reaction or a different inert organic solvent such as ether, and dried.
  • the salt obtained can be simply treated with a base and extracted with an organic solvent to give the free optically active compound in high optical purity.
  • the base may be organic or inorganic only if it is a stronger base compared with compound (II) and is preferably an inorganic base such as the hydroxides, carbonates and hydrogen carbonates of sodium, potassium and so on.
  • a halogenated hydrocarbon such as dichloromethane, chloroform, 1,2-dichloroethane, etc., are preferred.
  • optical purity of the product can be deter­mined by high performance liquid chromatography (HPLC) as described above (see, for example, EP-A-206,283 and JP-A-­62-87577).
  • HPLC high performance liquid chromatography
  • the optical purity of compound (II) after 3 to 4 recrystallization runs was more than 98% e.e.
  • the yield of the optically active compound can be increased by recycling of the recrystallization mother liquid or the second crop of crystals and is not less than 30% based on starting compound (II).
  • the optical resolution reagent compound (IV) can be easily recovered in the following manner.
  • the aqueous layer after isolation of the free optically active compound or the aqueous layer which may be obtained after extracting the benzoxazine compound (II) by the method as stated above from a salt mixture predominantly composed of undesired optical isomer of compound (II) is first acidified, concentrated if desired, and extracted with an organic solvent such as chloroform, 1,2-dichloroethane or the like.
  • the compound (IV) thus recovered gave melting point, optical rotation and other physical values in agreement with the known values, indicating that the compound can be recovered in high purity.
  • the recovered compound (IV) was again used in the optical resolution procedure, no deterioration in the efficiency of resolution was observed at all.
  • the ethyl acetate was removed under reduced pressure and the oily residue was purified over silica gel (50 g) column chromatography using chloroform (the bottom layer after shaking with concentrated aqueous ammonia) as the eluent.
  • the mixture was stirred at -60 to -50°C for further an hour, then washed twice with 10 ml portions of cold 5% aqueous citric acid solution and 10 ml of cold dilute aqueous ammonia (the same as mentioned hereinbefore).
  • Example 6 The procedure of Example 6 was repeated except that recrystallization was repeated 4 times, and the crystallization mother liquid (ML) and second crop of crystals were recycled to the next lot (see the flow diagram as shown in Figure 1). As a result, (-)-FBO was obtained in Run 3 with a yield of 30% and an optical purity of 99% e.e.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP88112555A 1987-08-03 1988-08-02 Verfahren zur Herstellung von Benzoxazin Derivaten Withdrawn EP0304684A1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP194018/87 1987-08-03
JP19401787 1987-08-03
JP19401887 1987-08-03
JP194017/87 1987-08-03

Publications (1)

Publication Number Publication Date
EP0304684A1 true EP0304684A1 (de) 1989-03-01

Family

ID=26508246

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88112555A Withdrawn EP0304684A1 (de) 1987-08-03 1988-08-02 Verfahren zur Herstellung von Benzoxazin Derivaten

Country Status (8)

Country Link
US (1) US4880926A (de)
EP (1) EP0304684A1 (de)
KR (1) KR960008243B1 (de)
CA (1) CA1304081C (de)
DK (1) DK429588A (de)
FI (1) FI883600A (de)
IE (1) IE61909B1 (de)
NO (1) NO883398L (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
US5567843A (en) * 1995-03-20 1996-10-22 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid)azoles and 2-aminoaryl aminobenz(ox, thi, imid)azoles
US5739344A (en) * 1996-12-06 1998-04-14 The Dow Chemical Company Preparation of an aminoarylaminoarazole

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2381935A (en) * 1940-11-16 1945-08-14 Eastman Kodak Co Process for producing morpholine compounds
DE1809454A1 (de) * 1968-11-18 1970-07-09 Merck Anlagen Gmbh 2-Methyl-3-aryl-benzazine und Verfahren zu ihrer Herstellung
EP0047005B1 (de) * 1980-09-02 1984-11-14 Daiichi Seiyaku Co., Ltd. Benzoxazin-Derivate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2381935A (en) * 1940-11-16 1945-08-14 Eastman Kodak Co Process for producing morpholine compounds
DE1809454A1 (de) * 1968-11-18 1970-07-09 Merck Anlagen Gmbh 2-Methyl-3-aryl-benzazine und Verfahren zu ihrer Herstellung
EP0047005B1 (de) * 1980-09-02 1984-11-14 Daiichi Seiyaku Co., Ltd. Benzoxazin-Derivate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOUBEN-WEYL, METHODEN DER ORGANISCHEN CHEMIE *
MONATSHEFTE FÜR CHEMIE *
PATENT ABSTRACTS OF JAPAN *
REAGENTS FOR ORGANIC SYNTHESIS *

Also Published As

Publication number Publication date
DK429588A (da) 1989-02-04
NO883398L (no) 1989-02-06
IE882357L (en) 1989-02-03
KR960008243B1 (ko) 1996-06-21
CA1304081C (en) 1992-06-23
NO883398D0 (no) 1988-08-01
FI883600A (fi) 1989-02-04
DK429588D0 (da) 1988-08-02
FI883600A0 (fi) 1988-08-01
IE61909B1 (en) 1994-11-30
KR890003717A (ko) 1989-04-17
US4880926A (en) 1989-11-14

Similar Documents

Publication Publication Date Title
US4985557A (en) Optically active pyridobenzoxazine derivatives and intermediates thereof
US4778891A (en) Certain pyrano (3,4-f)-indolizine derivatives
KR101540435B1 (ko) 발리올아민의 입체선택적 합성
US4833273A (en) Process for the resolution of 1-aminoindanes
CA1185244A (en) .beta.-LACTAM ACETIC ACID DERIVATIVES, THE PROCESS FOR PREPARING THEM, AND THEIR USE AS INTERMEDIATES FOR 1- AZABICYCLO¬3.2.0|HEPT-2-ENE ANTIBIOTICS
US5179212A (en) Process for the preparation of 3-pyrrolidinols and intermediates therefor
US4880926A (en) Optical resolution of benzoxazines
JP2000509068A (ja) エナンチオマーとして純粋なアゼチジン―２―カルボン酸の改良された製造方法
GB2036744A (en) Eburnane derivatives
US4895944A (en) Benzoxazine intermediates
US4314939A (en) Process for the preparation of 15-hydroxyimino-E-homoeburnane and intermediates therefor
KR0163770B1 (ko) 3,4-에폭시부티레이트의 제조 방법 및 이를 위한 중간체
US5981794A (en) γ-oxo-homophenylalanine derivatives and process for producing homophenylalanine derivatives by reducing the same
ITMI981796A1 (it) Procedimento per la preparazione di r-(-)-carnitina
NO175744B (no) Fremgangsmåte for enantiospesifikk syntese av mellomprodukter for heksahydrobenzo(d)nafto(2,1-b)azepiner
JP2746926B2 (ja) ベンゾオキサジン誘導体の製法
US5959141A (en) 1-amino-2-hydroxycycloalkanecarboxylic acid derivatives
CN113943240A (zh) 一种布瓦西坦的新制备方法
JPH0692918A (ja) ２−アミノメチルシクロプロパン−１−カルボン酸類
JPH07228549A (ja) 新規な４−アリール−２，３−ジヒドロキシ酪酸誘導体及びその製造方法
KR19990047362A (ko) (-)-3(s)-메틸피리도 벤즈옥사진 중간 유도체의 제조방법
JPH0217165A (ja) （２ｓ，３ｒ）−３−アミノ−２−アシルオキシ−４−フェニルブチロニトリル誘導体およびその製造方法
US6281379B1 (en) Process for producing norstatin derivatives
KR100197163B1 (ko) 광학적으로 순수한 할로부티르산 에스테르의 제조방법
JPS5967252A (ja) 光学活性β−アミノイソ酪酸及びその誘導体の製造法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE

17P Request for examination filed

Effective date: 19890828

17Q First examination report despatched

Effective date: 19910701

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920114